Targeted Diagnostic Botox Injections Can Identify Trigger Sites for Migraine
By Elana Gotkine HealthDay Reporter
THURSDAY, May 9, 2024 -- Diagnostic targeted Botox injections have high positive predictive value for migraine trigger site localization, according to a study published in the May issue of Plastic and Reconstructive Surgery.
Hassan ElHawary, M.D., from the McGill University Health Centre in Montreal, and colleagues examined the diagnostic capacity of Botox in a sensitivity analysis performed on 40 patients receiving Botox for migraine trigger site localization followed by surgical decompression of affected peripheral nerves.
The researchers found that patients with successful Botox injections (defined as ≥50 percent improvement in Migraine Headache Index scores after injection) had significantly higher average reductions in migraine intensity, frequency, and Migraine Headache Index postsurgical deactivation. Use of Botox injection as a diagnostic modality for migraine headaches had sensitivity and specificity of 56.7 and 80.0 percent, respectively, in a sensitivity analysis. The positive and negative predictive values were 89.5 and 38.1 percent, respectively.
"Our study supports the value of preoperative Botox injections as a reliable diagnostic tool for identifying patients who will respond to migraine surgery, with a positive predictive value of nearly 90 percent," coauthor Jeffrey E. Janis, M.D., of The Ohio State University Wexner Medical Center in Columbus, said in a statement. "We recommend the routine use of diagnostic Botox injections as well as nerve blocks with the goal of confirming trigger sites and identifying patients who are more likely to benefit from migraine surgery."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Use of Acid-Suppression Therapy Linked to Migraine, Severe Headache
FRIDAY, April 26, 2024 -- Use of acid-suppression therapy is associated with higher odds of migraine or severe headache, according to a study published online April 24 in...
American Academy of Neurology, April 13-18
The annual meeting of the American Academy of Neurology was held this year from April 13 to 18 in Denver, drawing participants from around the world, including clinicians...
AAN: Half of Premenopausal Women Have Menstrual Migraines
FRIDAY, April 19, 2024 – More than half of premenopausal women report menstrual migraine (MM), according to a study presented at the annual meeting of the American Academy...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.